BS_KABQQA0T
Diffuse intrinsic pontine glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Diffuse intrinsic pontine glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Diffuse intrinsic pontine glioma
- overall_survival_months
- 8.47568988173456
- age_years
- 6.737
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.512
- E2F_TARGETS+0.447
- MYC_TARGETS_V2+0.435
- MYC_TARGETS_V1+0.363
- MITOTIC_SPINDLE+0.333
- WNT_BETA_CATENIN_SIGNALING+0.293
- NOTCH_SIGNALING+0.187
- SPERMATOGENESIS+0.140
- HEDGEHOG_SIGNALING+0.131
- UNFOLDED_PROTEIN_RESPONSE+0.079
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.557
- INTERFERON_GAMMA_RESPONSE-0.518
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.476
- TNFA_SIGNALING_VIA_NFKB-0.467
- COAGULATION-0.429
- COMPLEMENT-0.418
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.418
- IL6_JAK_STAT3_SIGNALING-0.392
- INFLAMMATORY_RESPONSE-0.392
- ALLOGRAFT_REJECTION-0.387
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-34-5927-01A-11R-1820-07 | — | cohortSQ1 | 0.909 |
| 2 | SRR11296849 | — | — | 0.907 |
| 3 | BS_M0QYNVK8 | high-grade glioma | — | 0.904 |
| 4 | BS_5P1TN10Z | Embryonal tumors | — | 0.901 |
| 5 | dd75267f-824e-4ddc-9056-cdf0f500d39b | — | — | 0.899 |
| 6 | BS_K25F4J3V | ATRT | — | 0.897 |
| 7 | ERR2208946 | — | — | 0.895 |
| 8 | TCGA-98-A53A-01A-11R-A262-07 | — | cohortSQ1 | 0.894 |
| 9 | SRR5088819 | — | — | 0.893 |
| 10 | SRR8613725 | — | E | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.512 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.447 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.435 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.363 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.333 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.293 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.187 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.131 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.079 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.063 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.033 | Temsirolimus | — uncovered |